These data allow the elucidation of mechanisms of response and resistance to ALK inhibition with lorlatinib in patients with relapsed/refractory ALK-mutated neuroblastoma and illustrate the utility of ctDNA analysis to track disease course under the selective pressure of targeted therapy and perhaps ultimately intervene preemptively before clinical disease progression. This evidence concerns the gene ALK and neuroblastoma.